American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia

Schizophrenia is a leading cause of disability worldwide, with an estimated lifetime prevalence of 0.7%. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia provides evidence-based pharmacological and nonpharmacological treatments to reduce mortality, morbidity, and psychosocial consequences. It emphasizes assessment and treatment planning in patient-centered care to improve outcomes.

Format: Paperback / softback
Length: 310 pages
Publication date: 03 November 2020
Publisher: American Psychiatric Association Publishing

Schizophrenia is a highly disabling condition globally, ranking among the top 20 causes of disability. According to estimates, the lifetime prevalence of schizophrenia ranges from approximately 0.7% to 1.2%, depending on various factors such as study location, demographic characteristics of the sample, case-finding approach, diagnostic confirmation method, and diagnostic criteria employed. The economic impact of schizophrenia is substantial, with an estimated annual cost of more than $150 billion in the United States based on 2013 data. Since the second edition of the guideline was published, additional research has expanded our understanding of effective and evidence-based interventions that can help mitigate the mortality, morbidity, and significant psychosocial and health consequences associated with this important psychiatric condition.

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia is a comprehensive resource designed to address these challenges. This guideline focuses specifically on evidence-based pharmacological and nonpharmacological treatments for schizophrenia, recognizing the importance of patient-centered care. It provides guidance on assessment and treatment planning, which are integral components of delivering high-quality care to individuals with schizophrenia. The guideline offers clear recommendations on implementing these interventions in clinical practice, with the ultimate goal of improving treatment outcomes and enhancing the quality of life for patients with this condition.

By adhering to the principles outlined in the guideline, healthcare professionals can provide comprehensive and individualized care to patients with schizophrenia, helping them achieve better mental health outcomes and improve their overall well-being. The guideline also emphasizes the importance of collaboration between mental health professionals, primary care providers, and other stakeholders to ensure a holistic approach to treatment and support for individuals with schizophrenia.

In conclusion, the American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia is a valuable tool for healthcare professionals seeking to improve the care and treatment of individuals with schizophrenia. By focusing on evidence-based interventions and patient-centered care, this guideline provides a roadmap for delivering high-quality care and improving the lives of individuals with this challenging psychiatric condition.

Weight: 858g
Dimension: 212 x 277 x 16 (mm)
ISBN-13: 9780890424698
Edition number: 3 Revised edition